Skip to main content
dna sequence computer

Translational Research and Interventional Oncology Research Program

The Translational Research and Interventional Oncology Research Program translates advances in mechanism-based research into improved detection methods and therapies for cancer. With a primary focus on lung cancer, melanoma and leukemia/lymphoma, the program is dedicated to new discoveries in early detection and molecular oncology, and genotype-driven early phase trials for all cancer types.

RESEARCH THEMES

The Translational Research and Interventional Oncology program is dedicated to translating our understanding of the molecular mechanisms of oncogenesis and tumor progression into novel therapeutic strategies for cancer. 

Developing early phase clinical trials for therapies directed at genetic changes in tumors

Investigating why some tumors become resistant to genetically targeted therapies and developing new strategies to prevent and overcome resistance

Applying and enhancing immune strategies and cellular therapies for cancer

Developing and evaluating screening methods and biomarkers for early detection of lung cancers

Meet the Program Members

The Translational Research and Interventional Oncology Program is the largest of the cancer center's formal research programs, with more than 50 members representing a range of clinical and translational cancer research areas. The program is led by Madan Jagasia, M.B.B.S., Young Kim, M.D., Ph.D., and Christine Lovly, M.D., Ph.D.

Featured Publications

Program News

May 11, 2018

Grant bolsters kidney cancer immunotherapy research

Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.
March 12, 2018

VICC study sheds new light on Von Hippel-Lindau syndrome

A new study by W. Kimryn Rathmell, MD, PhD, and colleagues, reveals a gene mutation’s role in Von Hippel-Lindau syndrome, a genetically inherited disease which causes tumor growth in several organs.

Seminars & Events

Calendar
Jun
27
Myeloid Working Group Seminar: Coleman Lindsley, MD, PhD

27 June 2018

Calendar
Nov
29
VICC Seminar Series: Vince Miller, MD

29 November 2018